A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-11-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-0649PMID 22068656PMCID PMC3227395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune parameters affecting the efficacy of chemotherapeutic regimens

  2011cited by this paper
• Impact of tumour volume on the potential efficacy of therapeutic vaccines.

  2011cited by this paper
• MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients

  2011cited by this paper
• Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.

  2011cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

  2009cited by this paper
• MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008influential reference
• Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

  2008cited by this paper
• Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

  2008influential reference
• Cancer Vaccines: Moving Beyond Current Paradigms

  2007influential reference
• Evolution of the human MUC1 oncoprotein.

  2007cited by this paper
• PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

  2007cited by this paper
• Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

  2007cited by this paper
• Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer: Small EJ, Schellhammer PF, Higano CS, et al (Univ of California San Francisco; Sharp Healthcare, San Diego, Calif; Eastern Virginia Med

  2007cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006cited by this paper
• A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• What Makes MUC1 a Tumor Antigen?

  2005cited by this paper
• Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer.

  2005cited by this paper
• Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

  2005cited by this paper
• Multiple Costimulatory Modalities Enhance CTL Avidity

  2005cited by this paper
• Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Poxvirus vaccines for cancer and HIV therapy

  2004influential reference
• Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

  2004cited by this paper
• Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy

  2003cited by this paper
• Carcinoembryonic antigen-based vaccines.

  2003cited by this paper
• Vaccine therapy of established tumors in the absence of autoimmunity.

  2003cited by this paper
• Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

  2002cited by this paper
• The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.

  2002cited by this paper
• Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

  2001cited by this paper
• The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

  2001cited by this paper
• Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

  2001cited by this paper
• Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.

  2001cited by this paper
• The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

  2000cited by this paper
• Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

  2000cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• A triad of costimulatory molecules synergize to amplify T-cell activation.

  1999cited by this paper
• Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.

  1997cited by this paper
• Recombinant poxvirus vaccines

  1993cited by this paper
• Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule.

  1989cited by this paper

• Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research

  2025cites this paper
• Promising future of breast cancer vaccine asking for multidisciplinary collaboration: a literature review

  2025cites this paper
• Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope

  2025cites this paper
• Current and future immunotherapy for breast cancer

  2024cites this paper
• Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells

  2024cites this paper
• Present and Future of Immunotherapy for Triple-Negative Breast Cancer

  2024cites this paper
• Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)

  2024cites this paper
• Paeoniflorigenone inhibits ovarian cancer metastasis through targeting the MUC1/Wnt/β-catenin pathway

  2024cites this paper
• Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside

  2024cites this paper
• Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination.

  2023cites this paper
• Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

  2023cites this paper
• Therapeutic Vaccines in Breast Cancer

  2023cites this paper
• Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies

  2022cites this paper
• Recent Progress on Therapeutic Vaccines for Breast Cancer

  2022cites this paper
• Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma

  2022cites this paper
• Gene Therapy Cargos Based on Viral Vector Delivery.

  2022cites this paper
• Nucleic acid vaccination strategies for ovarian cancer

  2022cites this paper
• Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

  2022cites this paper
• MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

  2022cites this paper
• Emerging immunotherapeutic strategies for the treatment of breast cancer

  2021cites this paper
• Oncolytic viruses: A novel treatment strategy for breast cancer

  2021cites this paper
• Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human

  2021cites this paper
• Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options.

  2021cites this paper
• Optimizing systemic therapy in metastatic breast cancer: implementation in daily practice and exploration of new drug targets

  2020cites this paper
• Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

  2020cites this paper
• The use of multi-omics data and approaches in breast cancer immunotherapy: a review.

  2020cites this paper
• Development of Therapeutic Vaccines for Ovarian Cancer

  2020cites this paper
• P-STAT3 and IL-17 in tumor tissues enhances the prognostic value of CEA and CA125 in patients with lung adenocarcinoma.

  2020cites this paper
• Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

  2019cites this paper
• MUC1 in Cancer Immunotherapy — New Hope or Phantom Menace?

  2019cites this paper
• A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

  2019cites this paper
• Cancer Vaccines

  2019cites this paper
• Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

  2019cites this paper
• A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

  2019cites this paper
• Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.

  2019cites this paper
• The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

  2018cites this paper
• Immunotherapy in Breast Cancer: the New Frontier

  2018cites this paper
• Implication of Soluble Forms of Cell Adhesion Molecules in Infectious Disease and Tumor: Insights from Transgenic Animal Models

  2018cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2018cites this paper
• Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies

  2018cites this paper
• Breast cancer vaccination comes to age: impacts of bioinformatics

  2018cites this paper
• Clinical utility of CA-125 in the management of uterine carcinosarcoma

  2018cites this paper
• Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

  2018cites this paper
• Immunotherapy in ovarian cancer.

  2017cites this paper
• Therapeutic cancer vaccines.

  2017cites this paper
• The Future in Ovarian Cancer: Advances in Immunotherapies

  2017cites this paper
• 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two

  2017cites this paper
• Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

  2017cites this paper
• Viral gene therapy for breast cancer: progress and challenges

  2017cites this paper
• Specific immunotherapy in ovarian cancer: a systematic review.

  2016cites this paper
• Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

  2016cites this paper
• Immunotherapy in Breast Cancer- Paving New Roads?

  2016cites this paper
• Immunotherapy in Breast Cancer

  2016cites this paper
• A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas

  2016cites this paper
• MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition

  2016cites this paper
• The Role of the Immune System in Ovarian Cancer and Implications on Therapy

  2016cites this paper
• Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies.

  2016cites this paper
• Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Elevated serum carcinoembryonic antigen and CA15-3 levels and the risk of site-specific metastases in metastatic breast cancer

  2016cites this paper
• Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond

  2016cites this paper
• Dendritic cell-based cancer immunotherapy for colorectal cancer.

  2016cites this paper
• Chordoma: The Quest for Better Treatment Options

  2016cites this paper
• The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer

  2015cites this paper
• Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack

  2015cites this paper
• Immunotherapeutic approaches to ovarian cancer treatment

  2015cites this paper
• Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model

  2015cites this paper
• Emerging immunotherapies for bladder cancer

  2015cites this paper
• The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

  2015cites this paper
• Immunotherapy for the Treatment of Breast Cancer

  2015cites this paper
• Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

  2015cites this paper
• Immunotherapy for Ovarian Cancer

  2015cites this paper
• Emerging immunotherapies in ovarian cancer.

  2015cites this paper
• Immunotherapeutic options on the horizon in breast cancer treatment.

  2015cites this paper
• M�C 1-��eci�c C�toto�ic � ����hoc�tes in Cancer �hera��� Induction and Challenge

  2015cites this paper
• Immunotherapy for Ovarian

  2015cites this paper
• Combating the Epigenome: Elucidation of Mechanisms Underlying Chemoresistance and Enhancing Tumor Immunogenicity

  2015cites this paper
• The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• Vaccinia Viral Vectors for Vaccines and Oncolytic Virotherapy

  2015cites this paper
• Immunotherapy for the Prevention and Treatment of Breast Cancer

  2015cites this paper
• Vaccination in gastrointestinal cancer

  2014cites this paper
• The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors

  2014cites this paper
• 4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques

  2014cites this paper
• Immunological Approaches for Treatment of Advanced Stage Cancers Invariably Refractory to Drugs

  2014cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• Investigating the role of PD-L1 pathway in human ovarian cancer

  2014cites this paper
• Therapeutic cancer vaccines.

  2014cites this paper
• Ovarian Cancer: the Prospect of Development of Vaccines Therapy

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2014cites this paper
• Emerging immunotherapy strategies in breast cancer.

  2014cites this paper
• Trial Watch

  2014cites this paper
• Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.

  2014cites this paper
• TWO Therapeutic Cancer Vaccines

  2014cites this paper
• Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

  2014cites this paper
• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

  2014cites this paper
• A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

  2014cites this paper
• Harnessing the immune system for the treatment of breast cancer

  2014cites this paper